Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Dec 02, 2021 5:19pm
168 Views
Post# 34192290

RE:RE:RE:The good and bad...IMO

RE:RE:RE:The good and bad...IMOTo use a different expression from years ago borrowed from a California winery commercial - We will market no products before their time for completion.  I whole heartedly agree with you companies that want a higher share price are capable of reaching it fairly easily.  If the cannabis market had waited until the companies were up and operating large fortunes would not have been made leading up to market launch.  Then lost in the inevitable return to reality.

But deepening ties with Baxter along with hinted DaVita involvement leads me to think the end game will be a sale to each of them.  So why would they hype the share price when as insiders they can't really sell until the end game is reached.  Indeed they can continue to accumulate at much lower prices until then.  A win-win for them.  Nobody seemed in a rush to get the share price up to $0.55 per share in order to take the "easier route" to a Nasdaq listing.  Very revealing and leads me to believe that's not the ultimate route.

Just my takeaways. 
<< Previous
Bullboard Posts
Next >>